NanoRepro: Another capital increase for the business with COVID-19 tests

Unsurprisingly, NanoRepro has increased its capital after the Marburg company’s share price recently increased significantly. The company announced on Friday that the expected proceeds from the issue will be used for pre-and interim goods financing for corona rapid tests. In addition, they want to invest in scientific studies to increase the credibility of rapid tests, so NanoRepro.

The company plans to issue up to 2.64 million new shares. NanoRepro has set the subscription price at 3.03 euros. Shareholders receive subscription rights and can subscribe to the company’s new shares at a ratio of 3.53 to 1. No comment is made on Friday about the subscription period.

“New shares not purchased by shareholders within the framework of the statutory subscription right are to be offered to selected investors as part of a private placement at a subscription price of EUR 3.03 per new share,” announced NanoRepro. One investor is said to have already declared its intention to “take over at least 660,110 new shares not subscribed by the existing shareholders as part of the subscription offer”.

The company had already carried out a capital increase in March – also to finance one COVID-19 rapid test that failed to meet expectations, at that time with a volume of just under 1.87 million euros.

Security data: NanoRepro
Chart analysis tools: click here!
Ticker symbol: NN6
WKN: 657710
ISIN: DE0006577109
NanoRepro – trade now on: comdirectcomdirect – flatexflatex – SmartbrokerSmart broker – Trade RepublicTrade Republic

Tip: Trade and invest better with TradingView charts

Related Articles

Back to top button